Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort
- 29 May 2012
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 78 (22), 1736-1742
- https://doi.org/10.1212/wnl.0b013e3182583022
Abstract
Objective: To investigate the rate of seropositivity of anti-JC virus (JCV) antibodies in a German multiple sclerosis (MS) cohort treated with natalizumab in the postmarketing setting and to assess anti-JCV serostatus in samples obtained before diagnosis of progressive multifocal leukoencephalopathy (PML). Methods: This was a blinded, retrospective cross-sectional and longitudinal analysis for anti-JCV antibodies using a confirmatory 2-step ELISA on 2,782 blood samples obtained from 2,253 patients nationwide for routine testing for anti-natalizumab antibodies during open-label treatment between 2007 and 2010. Results: Of the natalizumab-treated patients with MS, 58.8% tested positive for anti-JCV antibodies. The rate of seropositivity was higher in males and increased with age, with a plateau between age intervals 20–29 and 30–39 years. In longitudinal analyses, 19 of 194 (9.8%) patients converted from anti-JCV antibody-negative to seropositive status over 7.7 months; 4.7% reverted from antibody-positive to seronegative status over 7.9 months. Antibody levels, especially in the latter group, were low, indicating fluctuations around the lower cut point of the assay. Neither anti-JCV serostatus nor antibody levels were associated with immunosuppressive pretreatment, duration of natalizumab treatment, or anti-natalizumab antibodies. All samples obtained from 10 patients who developed PML were seropositive (13 samples before PML diagnosis [2.0–37.6 months]; 2 samples at diagnosis). Antibody levels in these samples were higher than those in samples from seropositive patients who did not develop PML. Conclusions: These data argue for the potential clinical utility of JCV serology for PML risk stratification. However, further investigations of fluctuations in serostatus and of antibody levels for a more precise understanding of the predictive value are warranted.Keywords
This publication has 13 references indexed in Scilit:
- Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasmaJournal of Clinical Virology, 2012
- Trends in stroke hospitalizations and associated risk factors among children and young adults, 1995–2008Annals of Neurology, 2011
- Anti‐John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY‐1Annals of Neurology, 2011
- Progressive multifocal leukoencephalopathy and natalizumabZeitschrift für Neurologie, 2011
- Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathyNeurology, 2011
- Functional Energetics of CD4+-Cellular Immunity in Monoclonal Antibody-Associated Progressive Multifocal Leukoencephalopathy in Autoimmune DisordersPLOS ONE, 2011
- Assay design and sample collection can affect anti‐John Cunningham virus antibody detectionAnnals of Neurology, 2010
- Anti‐JC virus antibodies: Implications for PML Risk StratificationAnnals of Neurology, 2010
- Assessment of JC virus DNA in blood and urine from natalizumab‐treated patientsAnnals of Neurology, 2010
- Myasthenia gravis: Reactivation of clinical disease and of automimmune factors after discontinuation of long‐term azathioprineAnnals of Neurology, 1985